Next Day Disclosure Return
Filed with HKEX · Stock code 2096 · · 7 pages · English
Simcere Pharmaceutical Group Limited on 6ix
Earlier from Simcere Pharmaceutical
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Notification letter and reply form to non-registered holders: notice of publication of interim report 2026
- Notification letter and reply form to registered shareholders: notice of publication of interim report 2026
- 2026 Interim report
- (Revised) Next Day Disclosure Return
Later from Simcere Pharmaceutical
- Voluntary announcement - entering into an exclusive promotion services agreement with lynk pharmaceuticals in respect of dermatological indications of zemprocitinib
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Voluntary announcement - new drug application (nda) of zemprocitinib for the treatment of rheumatoid arthritis was accepted by the national medical products administration
- Voluntary announcement - the clinical trial approval for SIM0709 (TL1A/il-23P19 bispecific antibody) issued by the german regulatory authority and ethics committee
- Voluntary announcement - the clinical trial approval for SIM0725 (CD122) issued by the national medical products administration
Follow Simcere Pharmaceutical into a list and get an email when it puts out news.
Follow Simcere Pharmaceutical